AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 595718 — intervention group
Group type: EXPERIMENTAL
Intervention: Buformin
Number of subjects: 100
Study 595718 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 100
Study 31951291 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based parenting programs focusing on behavioral and physical health
Number of subjects: 0
Study 31951291 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of parenting programs
Number of subjects: 0
Study 31951291 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial and organizational outcomes
Number of subjects: 0
Study 30817465 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise training (IET)
Number of subjects: 24
Study 26719349 — intervention group
Group type: EXPERIMENTAL
Intervention: Carer Support Needs Assessment Tool (CSNAT) intervention
Number of subjects: 681
Study 26719349 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 681
Study 25923550 — intervention group
Group type: EXPERIMENTAL
Intervention: Rociletinib (500 mg to 1000 mg twice daily)
Number of subjects: 130
Study 23889096 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of benazepril (0.45 mg/kg daily for 4 days)
Number of subjects: 12
Study 23889096 — intervention group
Group type: COMPARATOR
Intervention: Tablet formulation of benazepril (0.45 mg/kg daily for 4 days)
Number of subjects: 12
Study 21742089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon counterpulsation (IABC) initiated before primary PCI and continued for at least 12 hours
Number of subjects: 300
Study 21742089 — intervention group
Group type: COMPARATOR
Intervention: Routine PCI with standard-of-care medical therapy
Number of subjects: 300
Study 19738991 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 63
Study 19738991 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 63
Study 15699810 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone graft harvest
Number of subjects: 208
Study 15699810 — intervention group
Group type: COMPARATOR
Intervention: Graft site appearance assessment
Number of subjects: 208
Study 12074359 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat (40 mg)
Number of subjects: 22
Study 12074359 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (20 mg daily)
Number of subjects: 22
Study 10431554 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial combined hyperlipidemia (FCH) patients
Number of subjects: 430
Study 10431554 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 430
Study 10431554 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypertension
Number of subjects: 430
Study 10431554 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with secondary hypertension due to renal artery stenosis (RAS)
Number of subjects: 430
Study 8924548 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 300 mg twice a day (E1)
Number of subjects: 30
Study 8924548 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg tid (E2)
Number of subjects: 30
Study 8924548 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Theophylline 200 mg and Salbutamol 4 mg (E3)
Number of subjects: 30
Study 8924548 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Theophylline 100 mg and Salbutamol 2 mg (E4)
Number of subjects: 30
Study 8924548 — intervention group
Group type: COMPARATOR
Intervention: Placebo calcium lactate 300 mg tid (E5)
Number of subjects: 30
Study 1978872 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 10
Study 1978872 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 10
Study 1978872 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 10
Study 6105025 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (n=10)
Number of subjects: 20
Study 6105025 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (n=10)
Number of subjects: 20
Study 6105025 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid subjects (n=12)
Number of subjects: 20
Study 30266438 — intervention group
Group type: COMPARATOR
Intervention: Fear acquisition and fear generalization phase (day 1)
Number of subjects: 46
Study 30266438 — intervention group
Group type: COMPARATOR
Intervention: Extinction learning phase (day 2)
Number of subjects: 46
Study 30266438 — intervention group
Group type: COMPARATOR
Intervention: Extinction recall phase (day 3)
Number of subjects: 46
Study 27932240 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream once daily (superficial basal cell carcinoma, 6 weeks; nodular basal cell carcinoma, 12 weeks)
Number of subjects: 501
Study 27932240 — intervention group
Group type: COMPARATOR
Intervention: Excisional surgery (4-mm margin)
Number of subjects: 501
Study 27932240 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream once daily
Number of subjects: 501
Study 25216962 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA patches on all abdominal incisions
Number of subjects: 121
Study 25216962 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches on all abdominal incisions
Number of subjects: 121
Study 24063362 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 290
Study 24063362 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 290
Study 21880031 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q(®)
Number of subjects: 100
Study 21880031 — intervention group
Group type: COMPARATOR
Intervention: ProSeal
Number of subjects: 100
Study 18474393 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (INR 2.8-4.2)
Number of subjects: 186
Study 18474393 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/d and Warfarin (INR 2.0-2.5)
Number of subjects: 186
Study 18474393 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 160 mg/d
Number of subjects: 186
Study 17538059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention targeting multiple risk-related behaviors
Number of subjects: 2928
Study 17538059 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 2928
Study 15148146 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the subthalamic nucleus (STN)
Number of subjects: 23
Study 15148146 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term STN deep brain stimulation
Number of subjects: 23
Study 11795688 — intervention group
Group type: EXPERIMENTAL
Intervention: cream with phytoestrogens
Number of subjects: 30
Study 11795688 — intervention group
Group type: COMPARATOR
Intervention: placebo (cold cream)
Number of subjects: 30
Study 9709785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (285.6 mg of elemental iron/day)
Number of subjects: 108
Study 9709785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron plus intravenous iron supplementation (285.6 mg of elemental iron/day orally plus 102.5 mg of elemental iron/week intravenously)
Number of subjects: 108
Study 9709785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no iron supplementation)
Number of subjects: 108
Study 8071390 — intervention group
Group type: EXPERIMENTAL
Intervention: 600‐mg methocel tablet (sustained-release)
Number of subjects: 20
Study 8071390 — intervention group
Group type: COMPARATOR
Intervention: 300‐mg CAP/carbovax-coated tablet (immediate-release)
Number of subjects: 20
Study 8071390 — intervention group
Group type: EXPERIMENTAL
Intervention: 600‐mg sustained-release tablet
Number of subjects: 20
Study 8071390 — intervention group
Group type: COMPARATOR
Intervention: 300‐mg tablet b.i.d.
Number of subjects: 20
Study 2487031 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital interaction patterns (disagreement and anger exchanges)
Number of subjects: 0
Study 2487031 — intervention group
Group type: EXPERIMENTAL
Intervention: Defensiveness (including whining), stubbornness, and withdrawal from interaction
Number of subjects: 0
Study 29766748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) enriched 5% oil formulation with 0.25% δ‐9‐tetrahydrocannabinol (THC) 20:1
Number of subjects: 25
Study 29766748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) enriched 5% oil formulation with 0.83% THC 6:1
Number of subjects: 25
Study 28547573 — intervention group
Group type: EXPERIMENTAL
Intervention: TLIF procedure using autologous iliac crest bone grafts (ICBGs) alone (Group A)
Number of subjects: 48
Study 28547573 — intervention group
Group type: EXPERIMENTAL
Intervention: TLIF procedure using local bone from decompression site mixed with hydroxyapatite (Group B)
Number of subjects: 48
Study 28547573 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 48
Study 26617135 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutritional Support (EN)
Number of subjects: 120
Study 26617135 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutritional Support (PN)
Number of subjects: 120
Study 23354440 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (received < 26 Gy to the left and right parotids)
Number of subjects: 126
Study 23354440 — intervention group
Group type: COMPARATOR
Intervention: Group B (received < 26 Gy to either parotid)
Number of subjects: 126
Study 23354440 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 126
Study 23354440 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 126
Study 21905997 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS (20 Hz) over the left DLPFC (n = 10)
Number of subjects: 19
Study 21905997 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n = 9)
Number of subjects: 19
Study 18787350 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel at a dose of 100 mg/m(2) plus radiotherapy (group I)
Number of subjects: 61
Study 18787350 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (group II)
Number of subjects: 61
Study 16969042 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine; specific dosage and duration not mentioned
Number of subjects: 0
Study 12560435 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF plus ADM (doxorubicin)
Number of subjects: 506
Study 12560435 — intervention group
Group type: COMPARATOR
Intervention: CMF alone
Number of subjects: 506
Study 10218338 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy using the INSURE approach (Intubation‐SURfactant‐Extubation)
Number of subjects: 12
Study 8622034 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant brachytherapy (BRT)
Number of subjects: 164
Study 8622034 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (no BRT)
Number of subjects: 164
Study 2006722 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 10 mg kg‐1 h‐1
Number of subjects: 28
Study 2006722 — intervention group
Group type: COMPARATOR
Intervention: 1 MAC enflurane
Number of subjects: 28
Study 6216344 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (181 mg/kg intravenous daily for 6 days)
Number of subjects: 56
Study 6216344 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin (270 mg/kg intravenous daily for 6 days)
Number of subjects: 56
Study 6216344 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 56
Study 6216344 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin
Number of subjects: 56
Study 31204406 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sampling time (15 minutes)
Number of subjects: 151
Study 31204406 — intervention group
Group type: COMPARATOR
Intervention: Standard sampling time (30 minutes)
Number of subjects: 151
Study 28532895 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 512
Study 28532895 — intervention group
Group type: COMPARATOR
Intervention: Prevailing health education
Number of subjects: 512
Study 25942421 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist geriatric medical intervention (geriatrician assessment in acute units and further specialist management)
Number of subjects: 433
Study 25942421 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 433
Study 23407820 — intervention group
Group type: EXPERIMENTAL
Intervention: Active list management program consisting of a telephonic interview on 21 items to evaluate socioeconomic features, self‐perceived health status, social support, referral physician, accessibility and patients' satisfaction.
Number of subjects: 501
Study 23407820 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 501
Study 20052619 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression care management
Number of subjects: 479
Study 18406045 — intervention group
Group type: EXPERIMENTAL
Intervention: Initially suspicious DRE
Number of subjects: 2218
Study 18406045 — intervention group
Group type: COMPARATOR
Intervention: Initially normal DRE
Number of subjects: 2218
Study 17575485 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron injection
Number of subjects: 42
Study 17575485 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injection
Number of subjects: 42
Study 14752215 — intervention group
Group type: EXPERIMENTAL
Intervention: Butterbur root extract (Petadolex), 25 mg, two capsules twice a day
Number of subjects: 60
Study 14752215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11822760 — intervention group
Group type: EXPERIMENTAL
Intervention: Nolatrexed 725 mg/m2 per day (5-day continuous infusion every three weeks)
Number of subjects: 139
Study 11822760 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 40 mg/m2 weekly (short infusion)
Number of subjects: 139
Study 10672490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration at 50 m/s2
Number of subjects: 20
Study 10672490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration at 30 m/s2
Number of subjects: 20
Study 10672490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 20
Study 10672490 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 20
Study 10672490 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 20
Study 10672490 — intervention group
Group type: COMPARATOR
Intervention: Control (0 m/s2 vibration)
Number of subjects: 20
Study 9229824 — intervention group
Group type: EXPERIMENTAL
Intervention: Eiconol (polyunsaturated fatty acids of omega-3 class) for two weeks
Number of subjects: 13
Study 9229824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8209058 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin inhalation (3.33 x 10(‐4) M)
Number of subjects: 24
Study 3533561 — intervention group
Group type: EXPERIMENTAL
Intervention: urapidil
Number of subjects: 40
Study 3533561 — intervention group
Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 40
Study 30300104 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed quit messages
Number of subjects: 182
Study 30300104 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed quit messages
Number of subjects: 182
Study 27494094 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific training in combination with a cognitive behavioural approach
Number of subjects: 75
Study 27494094 — intervention group
Group type: COMPARATOR
Intervention: Prescribed physical activity
Number of subjects: 75
Study 25282031 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg 3 times daily
Number of subjects: 420
Study 25282031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 22429566 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex
Number of subjects: 84
Study 22429566 — intervention group
Group type: COMPARATOR
Intervention: CinnoVex
Number of subjects: 84
Study 22429566 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 19607755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 171
Study 19607755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy
Number of subjects: 171
Study 19607755 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nefazodone and Cognitive Behavioral Analysis System of Psychotherapy
Number of subjects: 171
Study 19607755 — intervention group
Group type: COMPARATOR
Intervention: No dyadic discord (MAS score <= 2.36)
Number of subjects: 171
Study 19607755 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 171
Study 18346608 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 10
Study 18346608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 10
Study 16477764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (200 mg daily for 15 months)
Number of subjects: 100
Study 16477764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12189442 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion (3 g in 10 ml saline)
Number of subjects: 20
Study 12189442 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 20
Study 10341457 — intervention group
Group type: EXPERIMENTAL
Intervention: Female physicians
Number of subjects: 510
Study 10341457 — intervention group
Group type: COMPARATOR
Intervention: Male physicians
Number of subjects: 510
Study 8596497 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil-enriched diet
Number of subjects: 14
Study 8596497 — intervention group
Group type: COMPARATOR
Intervention: Margarine-enriched diet
Number of subjects: 14
Study 1955626 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 tablets of the supplement a day for three menstrual cycles
Number of subjects: 44
Study 1955626 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 tablets of the supplement a day for three menstrual cycles
Number of subjects: 44
Study 1955626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30345295 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking training (TW)
Number of subjects: 95
Study 30345295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking training (NW)
Number of subjects: 95
Study 30345295 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance and Nordic walking training (RES+NW)
Number of subjects: 95
Study 30345295 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 95
Study 29952499 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening
Number of subjects: 332
Study 29952499 — intervention group
Group type: COMPARATOR
Intervention: No music listening (control)
Number of subjects: 332
Study 24690514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 64
Study 23026843 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel besylate 75 mg
Number of subjects: 40
Study 23026843 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel bisulfate 75 mg
Number of subjects: 40
Study 20565562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Number of subjects: 926
Study 20565562 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 926
Study 17899308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cevimeline hydrochloride 30 mg three times per day for 10 weeks
Number of subjects: 50
Study 17899308 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 50
Study 17899308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cevimeline hydrochloride
Number of subjects: 50
Study 16871247 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 5 mg titrated to 20 mg daily
Number of subjects: 397
Study 16871247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 14520697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ile/Val or Val/Val genotype in gastric cancer patients
Number of subjects: 212
Study 14520697 — intervention group
Group type: EXPERIMENTAL
Intervention: Val/Val genotype
Number of subjects: 212
Study 14520697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ile/Val genotype
Number of subjects: 212
Study 14520697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ile/Val or Val/Val genotype
Number of subjects: 212
Study 14520697 — intervention group
Group type: EXPERIMENTAL
Intervention: HER-2 genotype
Number of subjects: 212
Study 10937676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (higher doses proposed, at least four to eight-fold that of the dose efficacious in an oestrogen-receptor dependent mechanism)
Number of subjects: 0
Study 8992696 — intervention group
Group type: COMPARATOR
Intervention: Room air (group I)
Number of subjects: 70
Study 8992696 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen (group II)
Number of subjects: 70
Study 8992696 — intervention group
Group type: COMPARATOR
Intervention: Comparison of groups
Number of subjects: 70
Study 1431597 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (15 g/day for 40 days)
Number of subjects: 20
Study 1431597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 20
Study 3883690 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 gel (Prostaglandin E2)
Number of subjects: 30
Study 30368585 — intervention group
Group type: EXPERIMENTAL
Intervention: BNC105P 12 mg/m2 with gemcitabine 1000 mg/m2 and carboplatin AUC4
Number of subjects: 15
Study 30368585 — intervention group
Group type: EXPERIMENTAL
Intervention: BNC105P 16 mg/m2 (maintenance treatment)
Number of subjects: 15
Study 30368585 — intervention group
Group type: EXPERIMENTAL
Intervention: BNC105P 800 mg/m2 with gemcitabine and carboplatin AUC4
Number of subjects: 15
Study 30368585 — intervention group
Group type: EXPERIMENTAL
Intervention: BNC105P 1000 mg/m2 with gemcitabine and carboplatin AUC4
Number of subjects: 15
Study 29359856 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil injection administered i.v. 10 min after transfer to recovery room
Number of subjects: 2
Study 29359856 — intervention group
Group type: COMPARATOR
Intervention: No antidote injected (Control group)
Number of subjects: 2
Study 29359856 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil injection
Number of subjects: 2